-
2022-501600-10-00
5
2023-02-07
Atrial fibrillation and Chronic Kidney Disease stage 5
-
2023-504885-50-00
5
2022-11-07
Treatment of children with chronic kidney disease and proteinuria
-
2023-503442-30-00
5
2022-10-14
Multiple Myeloma
-
2023-505512-37-00
5
2022-06-07
Acute Myeoloid Leukemia
-
2023-508815-22-00
5
2022-02-25
Familial Chylomicronemia Syndrome
-
2023-505497-14-00
4
2021-12-09
Proteinuric glomerular diseases including:
•Focal segmental glomerulo
-
2023-507164-39-00
6
2021-12-01
Induction of labour
-
2024-516728-32-00
10
2021-10-29
Indolent Systemic Mastocytosis and SSM
-
2024-518775-54-00
6
2021-10-05
Rheumatoid arthritis
-
2024-511651-17-00
4
2021-09-21
Myelodysplastic syndrome
-
2024-510615-29-00
5
2021-05-24
Chronic active antibody-mediated rejection in kidney transplant recipi
-
2022-501874-21-00
6
2020-12-15
Takotsubo syndrome
-
2024-511053-22-00
4
2020-05-04
Primary sclerosing cholangitis (PSC)
-
2023-504201-36-00
10
2018-12-21
Defined by parent protocol. The study will enroll all adult and paedia
-
2023-508128-37-00
5
2017-07-19
All patients who have been treated with Novartis or Penn CAR T-cell th
-
2024-517719-65-00
4
2017-02-01
Resectable pancreatic head cancer
-
2024-515626-92-00
4
2013-10-18
recurrent/progressive medulloblastoma, ependymoma and atypical teratoi
-
2025-522598-12-00
10
2025-12-17
Untreated Metastatic Pancreatic Ductal Adenocarcinoma
-
2024-520407-27-00
5
2025-10-23
X-Linked Protoporphyria (XLP)
-
2024-512914-16-00
5
2025-09-12
Relapsing-remitting Multiple Sclerosis
-
2025-520520-17-00
5
2025-09-05
Heterozygous familial hypercholesterolaemia
-
2024-517605-91-00
3
2025-05-26
advanced liver fibrosis
-
2024-514292-18-00
5
2025-03-24
Primary Sclerosing Cholangitis (PSC)
-
2023-505394-32-00
5
2025-02-06
chronic graft versus host disease